PMS-SALBUTAMOL 1 MG
SALBUTAMOL (SALBUTAMOL SULFATE) : 1 MG · DIN 02208229 · PHARMASCIENCE INC
Health Canada status: MARKETED
What is PMS-SALBUTAMOL?
PMS-SALBUTAMOL 1 MG contains SALBUTAMOL (SALBUTAMOL SULFATE) : 1 MG. It is listed in the Health Canada Drug Product Database under DIN 02208229, held by PHARMASCIENCE INC, supplied as SOLUTION for INHALATION administration. Health Canada currently lists it as marketed, status dated 07-May-2010. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PMS-SALBUTAMOL used for?
Treatment of severe bronchospasm associated with exacerbations of chronic bronchitis and bronchial asthma. Used by 'wet' nebulization.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02208229 |
|---|---|
| Brand name | PMS-SALBUTAMOL |
| Generic / active ingredient | SALBUTAMOL (SALBUTAMOL SULFATE) : 1 MG |
| Manufacturer | PHARMASCIENCE INC |
| Strength | 1 MG |
| Dosage form | SOLUTION |
| Route of administration | INHALATION |
| Schedule | Prescription |
| ATC code | R03AC02 SALBUTAMOL |
| AHFS class | 12:12.08.12 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 07-May-2010 |
| Original market date | 1996-12-31 00:00:00 |
How is it administered?
Administered via nebulizer or IPPV. Adults/Adolescents: 2.5 mg every 4-6 hours as needed (max 4x/day). Children (5-12): 1.25 mg to 2.5 mg every 4-6 hours as needed (max 4x/day).
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not specified in the provided text (refer to Storage and Stability section 13, not fully detailed in snippet).
How is it supplied?
Polynebs (unit dose) presentation.
Contraindications
Hypersensitivity to the drug or ingredients; tachyarrythmias; use as a tocolytic in patients at risk of premature labour or threatened abortion.
Warnings and precautions
Potential for paradoxical bronchospasm, serious hypokalemia, and metabolic changes (hyperglycemia). Caution in patients with cardiovascular disorders, diabetes, or hyperthyroidism.
Is SALBUTAMOL in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by SANIS HEALTH INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code R03AC02 SALBUTAMOL. 11 of 63 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-SALBUTAMOL HFA | 100 MCG | METERED-DOSE AEROSOL | APOTEX INC | MARKETED | DIN 02245669 |
| PMS-SALBUTAMOL | 0.5 MG | SOLUTION | PHARMASCIENCE INC | MARKETED | DIN 02208245 |
| PMS-SALBUTAMOL | 2 MG | SOLUTION | PHARMASCIENCE INC | MARKETED | DIN 02208237 |
| SALBUTAMOL HFA | 100 MCG | METERED-DOSE AEROSOL | SANIS HEALTH INC | MARKETED | DIN 02419858 |
| TEVA-SALBUTAMOL HFA | 100 MCG | METERED-DOSE AEROSOL | TEVA CANADA LIMITED | MARKETED | DIN 02326450 |
| TEVA-SALBUTAMOL STERINEBS P.F. | 1 MG | SOLUTION | TEVA CANADA LIMITED | MARKETED | DIN 01926934 |
| TEVA-SALBUTAMOL STERINEBS P.F. | 2 MG | SOLUTION | TEVA CANADA LIMITED | MARKETED | DIN 02173360 |
| VENTOLIN DISKUS | 200 MCG | POWDER | GLAXOSMITHKLINE INC | MARKETED | DIN 02243115 |
| VENTOLIN HFA | 100 MCG | METERED-DOSE AEROSOL | GLAXOSMITHKLINE INC | MARKETED | DIN 02241497 |
| VENTOLIN RESPIRATOR SOLUTION | 5 MG | SOLUTION | GLAXOSMITHKLINE INC | MARKETED | DIN 02213486 |
Who else supplies SALBUTAMOL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. SALBUTAMOL appears in 2807 registered pack listings across 14 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.